Literature DB >> 476310

Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). I. Response and toxicity in four different regimens.

T Büchner, D Urbanitz, W Hiddemann, D Kamanabroo, R Meister, L Balleisen, U Delvos, E M Lagrèze, U Schmitz-Huebner, H Schulte, J van de Loo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 476310     DOI： 10.1007/bf01008088

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


× No keyword cloud information.
  15 in total

Review 1.  Approaches to the treatment of acute leukemia and lymphoma in adults.

Authors:  G P Bodey; V Rodriguez
Journal:  Semin Hematol       Date:  1978-07       Impact factor: 3.851

2.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Authors:  J W Yates; H J Wallace; R R Ellison; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

3.  Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside.

Authors:  P A Cassileth; M E Katz
Journal:  Cancer Treat Rep       Date:  1977-11

4.  [Clinical and cell kinetic data on the combination of cytosine arabinoside with daunorubicin, isosfamide, thioguanine, and vincristine for remission induction and maintenance in patients with acute myelocytic leukaemia (author's transl)].

Authors:  T h Büchner; D Kamanabroo; D Urbanitz; W Hiddemann; J van de Loo
Journal:  Blut       Date:  1978-06-20

5.  High remission-induction rate in acute myeloid leukaemia.

Authors:  R P Gale; M J Cline
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

6.  Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system.

Authors:  D H Ho; N S Brown; J Benvenuto; K B McCredie; D Buckels; E J Freireich
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

7.  Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.

Authors:  P J Burke; J E Karp; H G Braine; W P Vaughan
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

8.  Treatment of acute leukemia in adults.

Authors:  B D Clarkson; M D Dowling; T S Gee; I B Cunningham; J H Burchenal
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

10.  Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.

Authors:  J K Rees; R M Sandler; J Challener; F G Hayhoe
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640
View more
  2 in total

1.  Intensified remission induction therapy for acute nonlymphocytic leukemia (ANLL). Treatment report on 60 patients.

Authors:  D Urbanitz; T Büchner; D Kamanabroo; W Hiddemann; H Schulte; J van de Loo
Journal:  Blut       Date:  1981-08

2.  Immunotherapy in the treatment of acute myelogenous leukemia (AML): rationale, results and future prospects.

Authors:  D Urbanitz; T Büchner; H Pielken; J van de Loo
Journal:  Klin Wochenschr       Date:  1983-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.